# A Call for Use of Lipid Fractionation Studies in Patients With Abnormal Standard Lipid Profiles

**Authors:** Megan Kawamura, Isabel Casimiro

PMC · DOI: 10.1210/jcemcr/luaf117 · 2025-07-10

## TL;DR

A patient with abnormal cholesterol levels and health issues was better treated using detailed lipid studies beyond standard tests.

## Contribution

The paper advocates for lipid fractionation studies to improve treatment in patients with abnormal lipid profiles.

## Key findings

- Lipid fractionation revealed abnormal small, dense LDL particles in a patient with normal standard lipid tests.
- Combining three cholesterol drugs improved lipid values and symptoms in this patient.
- Lipid fractionation studies provided actionable insights not captured by traditional lipid panels.

## Abstract

A 54-year-old female individual with a history of hyperlipidemia, hypothyroidism, latent autoimmune diabetes of the adult (LADA) with hypoglycemia unawareness, vitiligo, and asthma presented with exercise-limiting pleuritic chest pain and dyspnea. She underwent a full pulmonary and cardiac workup locally and at Mayo Clinic, which were normal and negative for pulmonary embolism and showed no evidence of cardiac ischemia. Her family history and abnormal lipid panels suggested possible familial hypercholesterolemia by Dutch criteria. Lipid fractionation studies were done to further assess abnormal lipid levels and symptoms, as she lives a generally healthy and active lifestyle. Lipid fractionation studies revealed abnormal small, dense (sdLDL) and low-density lipoproteins (LDL) particle numbers. She was started on a triple cholesterol management regimen of ezetimibe, evolocumab, and bempedoic acid, which improved lipid fractionation values and symptoms. This case highlights the utility of using lipid fractionation studies in addition to traditional lipid panels to best treat patients with abnormal lipid panels on lipid-lowering therapy.

## Linked entities

- **Chemicals:** ezetimibe (PubChem CID 150311), bempedoic acid (PubChem CID 10472693)
- **Diseases:** hyperlipidemia (MONDO:0021187), hypothyroidism (MONDO:0005420), vitiligo (MONDO:0008661), asthma (MONDO:0004979), familial hypercholesterolemia (MONDO:0005439)

## Full-text entities

- **Diseases:** hyperlipidemia (MESH:D006949), cardiac ischemia (MESH:D007511), hypoglycemia unawareness (MESH:D007003), familial hypercholesterolemia (MESH:D006938), pulmonary embolism (MESH:D011655), dyspnea (MESH:D004417), hypothyroidism (MESH:D007037), chest pain (MESH:D002637), asthma (MESH:D001249), LADA (MESH:D000071698), vitiligo (MESH:D014820)
- **Chemicals:** bempedoic acid (MESH:C581236), evolocumab (MESH:C577155), Lipid (MESH:D008055), cholesterol (MESH:D002784), ezetimibe (MESH:D000069438)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC12243849